Clinical trial · Observational
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
NCT06025045CI-TRIAL-00069328unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. This study plans to use ctDNA dynamic monitoring to detect minimal residual lesions during treatment, to demonstrate the application value of ctDNA dynamic monitoring in predicting the recurrence of ovarian cancer after PDS/IDS surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer Stage III | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
| Ovarian Cancer Stage IV | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 2 years DFS rate
- timeFrame
- 2 years
- description
- The recurrence rate of patients at two years after surgery
Secondary outcomes (1)
- measure
- DFS
- timeFrame
- 2 years
- description
- Disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. ≥ 18 years old. 2. Patients diagnosed with stage IIIC-IVA ovarian cancer through pathological examination. 3. The participant has read and fully understands the patient information, and has signed the informed consent form. 4. The patient is willing to undergo primary debulking surgery (PDS) or interval debulking surgery（IDS）. - Exclusion Criteria: 1. Other tumors have been detected within the last 5 years. 2. Organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants. 3. Patients was deemed unsuitable to participate in this study by other researchers. 4. Patients who have previously received neoadjuvant chemotherapy or targeted therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.